GEN - Genetic Engineering and Biotechnology News

StockWatch: Nektar’s Rezpeg Sparks a Sweet “Comeback Story”

Nektar Therapeutics sees its stock nearly double after announcing positive Phase IIb data for its lead pipeline candidate, ...

Ocular Therapeutix(TM) Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD

AXPAXLI (TM) (also known as OTX-TKI) is an investigational, bioresorbable, intravitreal hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic ...

Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD

First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to an approved anti-VEGF ...

Vidac Pharma Initiates In Vivo Pre-Clinical Program in Psoriasis, Expanding Its HK2/VDAC Platform Beyond Oncology

Study to be conducted by PharmaLegacy, a leading Contract Research Organization The scientific rationale for evaluating ...

Quorum Cyber’s 2026 Global Cyber Risk Outlook Reveals Cyber Crime Enters An Industrial Phase

AI and Ransomware Drive a 30% Rise in New Groups as AI-Enabled Tooling Accelerates Attacks, Raising the Stakes for ...

Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ETDetailed SOL-1 data to be presented at the 49th Macula Society ...

Ocular Therapeutix(TM) to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be ...